ring bonds :
1-2 1-6 1-7 2-3 3-4 4-5 5-6 7-8 8-9 9-18 18-20
exact/norm bonds :
1-7 7-8 8-9 9-18 10-11 15-16 15-17 18-19 18-20
exact bonds :
8-10 10-12 12-13 13-14 13-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L10 STRUCTURE UPLOADED

=> dis
L10 HAS NO ANSWERS
L10 STR



G1 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> s L10 full

```
FULL SEARCH INITIATED 13:17:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4078 TO ITERATE

100.0% PROCESSED     4078 ITERATIONS                                 15 ANSWERS
SEARCH TIME: 00.00.01

L11          15 SEA SSS FUL L10

=> fil hcap uspatful
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             863.20     863.41

FILE 'HCAPLUS' ENTERED AT 13:17:56 ON 02 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:17:56 ON 02 MAY 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> L11
L12          3 L11

=> d L12 1-3 ibib abs hitstr
```

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:710798 HCAPLUS
DOCUMENT NUMBER: 145:167297
TITLE: Preparation of macrocyclic lactones for treatment of β-amyloid related disease
INVENTOR(S): Betschart, Claudia; Lerchner, Andreas; Machauer, Rainer; Rueeger, Heinrich; Tintelnot-Blomley, Marina; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074950	A1	20060720	WO 2006-EP280	20060113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: GB 2005-682 A 20050113
GB 2005-20165 A 20051004

OTHER SOURCE(S): MARPAT 145:167297
GI



I

AB Title compds. [I; R1 = CHReCONRaRb, (CH2)kNRcRd; k = 0-2; Ra, Rb = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl; Rc, Rd = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, chroman-4-yl, isochroman-4-yl, 1,3,4,5-tetrahydrobenzo[c]oxepin-5-yl, etc.; RaRbN, RcRdN = (substituted) pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl; Re = (substituted) alkyl, cycloalkyl, etc.; R2 = H, alkyl; R3 = H, alkyl, (substituted) AO2CNH, etc.; A = alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, etc.; Ar = (substituted) (hetero)aryl; U = bond, O, CF2, CHF, cyclopropylene, etc.; V1 = H, V2 = OH; V1V2 = O; X = (substituted) alkylene, cycloalkylene, piperidinylene, pyrrolidinylene, etc.; X1 = C(Rf)2; Rf = H, F, (substituted) alkyl, alkoxyalkyl, etc.; Y = bond, O, SO2, etc.; Z = O, CH2, CF2, CHF, cyclopropylene, bond; ring contains 14-17 atoms], were prepd. Thus, (S)-4-[(R)-1-hydroxy-2-(3-isopropylbenzylamino)ethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.1*6,10*]henicosa-1(19),6,8,10(21),16(20),17-hexaen-2-one [prepn. from [(1S,2R)-1-(3-allylbenzyl)-3-[benzyloxycarbonyl-(3-isopropylbenzyl)amino]-2-hydroxypropyl]carbamic acid tert-Bu ester and 2-allylamino-6-methylisonicotinic acid hydrochloride outlined] inhibited cellular release of amyloid peptide 1-40 with IC50 = 0.04 nM.

IT 900797-95-7P 900797-96-8P 900797-97-9P
900797-98-0P 900797-99-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of macrocyclic lactones for treatment of β-amyloid related disease)

RN 900797-95-7 HCAPLUS
CN 11-Oxa-3,16,18-triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl-γ-hydroxy-19-methoxy-α-methyl-2-oxo-, (αR,γS,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 900797-96-8 HCAPLUS
CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),15,18-hexaene-4-butanamide, N-butyl-γ-hydroxy-18-methoxy-α-methyl-2-oxo-, (αR,γS,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 900797-97-9 HCAPLUS
CN 3,16,18-Triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl-γ-hydroxy-19-methoxy-α-methyl-2-oxo-, (αR,γS,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 900797-98-0 HCAPLUS
CN 3,16,18-Triazatricyclo[15.3.1.16,10]docosa-1(21),6,8,10(22),16,19-hexaene-4-butanamide, N-butyl-γ-hydroxy-α,19-dimethyl-2-oxo-, (αR,γS,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 900797-99-1 HCAPLUS
CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),15,18-hexaene-4-butanamide, N-butyl-γ-hydroxy-α,18-dimethyl-2-oxo-, (αR,γS,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 900798-76-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic lactones for treatment of β-amyloid related disease)

RN 900798-76-7 HCAPLUS
CN 3,15,17-Triazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),12,15,18-heptaene-4-butanamide, N-butyl-γ-hydroxy-α,18-dimethyl-2-oxo-, (αR,γS,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:29320 HCAPLUS
DOCUMENT NUMBER: 142:134632
TITLE: Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
INVENTOR(S): Betschart, Claudia; Tintelnot-Blomley, Marina
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003106	A1	20050113	WO 2004-EP7247	20040702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253667	A1	20050113	AU 2004-253667	20040702
CA 2529571	A1	20050113	CA 2004-2529571	20040702
EP 1654241	A1	20060510	EP 2004-740596	20040702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1809542	A	20060726	CN 2004-80017405	20040702
BR 2004012286	A	20060919	BR 2004-12286	20040702
US 2006223745	A1	20061005	US 2005-561949	20051222
PRIORITY APPLN. INFO.:			GB 2003-15654 A	20030703
			WO 2004-EP7247 W	20040702

OTHER SOURCE(S): MARPAT 142:134632
GI



AB The preparation of macrocyclic compds., I, (R1 = alkyl, alkoxy, piperidinyl,

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

or pyrrolidinyl; R2, R4 = H, alkyl,cycloalkyl, aryl, heteroaryl etc or R2 and R4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group; R3 = H, alkyl; X1 = CH2; X2 = CH2, O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C1-4)alkyl; Y = (C1-8)alkylen or (C1-8)alkylenoxy(C1-6)alkylen, (C1-8)alkenylen or (C1-8)alkenylenoxy(C1-6)alkylen; Ar = a Ph ring optionally mono- di- or trisubstituted; Z = CO, A = a natural or unnatural alpha-amino-acid; and n is 0 or 1, or Z = SO2 and AA = an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylene group), and n is 1) are prepd. as aspartic protease inhibitors for the treatment of neurol. and vascular disorders related to beta-amyloid generation and/or aggregation.

IT 824429-16-5P 824429-24-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)

RN 824429-16-5 HCAPLUS
CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-10-oxo-, 7,7-dioxide, (αR,γS,9S,12S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824429-24-5 HCAPLUS
CN 8-Thia-4-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 824429-11-0P 824429-29-0P 824957-23-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)

RN 824429-11-0 HCAPLUS
CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-8,11-dioxo-, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 824429-29-0 HCAPLUS
CN 8-Thia-4-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 824957-23-5 HCAPLUS
CN 2-Oxa-7,10-diazabicyclo[11.3.1]heptadeca-1(17),13,15-triene-11-butanamide, N-butyl-γ-hydroxy-α,8-dimethyl-6,9-dioxo-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 824429-15-4P 824429-21-2P 824429-23-4P
824957-22-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)
RN 824429-15-4 HCAPLUS
CN 2-Oxa-9-thia-13-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-butanamide, N-butyl-γ-hydroxy-α,11-dimethyl-12-oxo-, 9,9-dioxide, (αR,γS,11S,14S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 824957-22-4 HCAPLUS
CN 2-Oxa-8,11-diazabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-7,10-dioxo-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 824429-21-2 HCAPLUS
CN 2-Oxa-9-thia-12-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-11-oxo-, 9,9-dioxide, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 824429-23-4 HCAPLUS
CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α-methyl-10-oxo-, 7,7-dioxide, (αR,γS,12S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2006:262229 USPATFULL
TITLE: Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
INVENTOR(S): Betschart, Claudia, Basel, SWITZERLAND
Tintelnot-Blomley, Marina, Maulburg, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006223745	A1	20061005	
APPLICATION INFO.:	US 2004-561949	A1	20040702	(10)
	WO 2004-EP7247		20040702	
			20051222	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-15654	20030703

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to macrocyclic compounds of formula (I), wherein R.sub.1, is (C.sub.1-8)alkyl, (C.sub.1-4)alkoxy(C.sub.1-4)alkyl, hydroxy(C.sub.1-6)alkyl, (C.sub.1-4)alkylthio(C.sub.1-4)alkyl, (C.sub.1-6)alkenyl, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.1-4)alkyl, piperidinyl or pyrrolidinyl, R.sub.2 and R.sub.4, independently, are hydrogen or optionally substituted (C.sub.1-8)alkyl, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.1-4)alkyl, aryl, aryl(C.sub.1-4)alkyl, heteroaryl or heteroaryl(C.sub.1-4)alkyl, or R.sub.2 and R.sub.4, together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R.sub.3 is hydrogen or (C.sub.1-4)alkyl, X.sub.1 is CH.sub.2, X.sub.2 is CH.sub.2, O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C.sub.1-4)alkyl, Y is (C.sub.1-8)alkylen or (C.sub.1-8)alkylenoxy(C.sub.1-6)alkylen, (C.sub.1-8)alkenylen or (C.sub.1-6)alkenylenoxy(C.sub.1-6)alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X.sub.1, and X.sub.2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is SO.sub.2, AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 824429-16-5P 824429-24-5P
(macrocyclic compds. having aspartic protease inhibiting activity and

L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)
pharmaceutical uses thereof)
RN 824429-16-5 USPATFULL
CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-10-oxo-, 7,7-dioxide, (αR,γS,9S,12S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824429-24-5 USPATFULL
CN 8-Thia-4-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 824429-11-0P 824429-29-0P 824957-23-5P
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)
RN 824429-11-0 USPATFULL
CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-8,11-dioxo-, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)



IT 824429-15-4P 824429-21-2P 824429-23-4P
824957-22-4P
(macrocyclic compds. having aspartic protease inhibiting activity and pharmaceutical uses thereof)
RN 824429-15-4 USPATFULL
CN 2-Oxa-9-thia-13-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-butanamide, N-butyl-γ-hydroxy-α,11-dimethyl-12-oxo-, 9,9-dioxide, (αR,γS,11S,14S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824429-21-2 USPATFULL
CN 2-Oxa-9-thia-12-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-butanamide, N-butyl-γ-hydroxy-α,10-dimethyl-11-oxo-, 9,9-dioxide, (αR,γS,10S,13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)



RN 824429-29-0 USPATFULL
CN 8-Thia-4-azabicyclo[13.3.1]nonadeca-1(19),15,17-triene-3-butanamide, N-butyl-γ-hydroxy-α,6-dimethyl-5-oxo-, 8,8-dioxide, (αR,γS,3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 824957-23-5 USPATFULL
CN
2-Oxa-7,10-diazabicyclo[11.3.1]heptadeca-1(17),13,15-triene-11-butanamide, N-butyl-γ-hydroxy-α,8-dimethyl-6,9-dioxo-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)



RN 824429-23-4 USPATFULL
CN 2-Oxa-7-thia-11-azabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α-methyl-10-oxo-, 7,7-dioxide, (αR,γS,12S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824957-22-4 USPATFULL
CN 2-Oxa-8,11-diazabicyclo[12.3.1]octadeca-1(18),14,16-triene-12-butanamide, N-butyl-γ-hydroxy-α,9-dimethyl-7,10-dioxo-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 3 USPATFULL on STN (Continued)

```
=> d que stat
L10             STR
```




```
G1 C,O,N


Structure attributes must be viewed using STN Express query preparation.
L11          15 SEA FILE=REGISTRY SSS FUL L10
L12           3 SEA L11


=> d his full

     (FILE 'HOME' ENTERED AT 13:10:49 ON 02 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 13:11:03 ON 02 MAY 2007
L1               STRUCTURE UPLOADED
                 DIS
L2             0 SEA SSS SAM L1
L3             0 SEA SSS FUL L1
L4               STRUCTURE UPLOADED
                 DIS
L5             0 SEA SSS FUL L4
L6               STRUCTURE UPLOADED
                 DIS
L7             0 SEA SSS FUL L6
L8               STRUCTURE UPLOADED
                 DIS
L9             0 SEA SSS FUL L8
L10              STRUCTURE UPLOADED
                 DIS
L11           15 SEA SSS FUL L10
```

```
     FILE 'HCAPLUS, USPATFULL' ENTERED AT 13:17:56 ON 02 MAY 2007
L12           3 SEA ABB=ON  PLU=ON  L11
                D L12 1-3 IBIB ABS HITSTR
                D QUE STAT

     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    1 MAY 2007  HIGHEST RN 934050-43-8
     DICTIONARY FILE UPDATES:   1 MAY 2007  HIGHEST RN 934050-43-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 2 May 2007  VOL 146 ISS 19
     FILE LAST UPDATED: 1 May 2007  (20070501/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE USPATFULL
     FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 May 2007 (20070501/PD)
     FILE LAST UPDATED: 1 May 2007 (20070501/ED)
     HIGHEST GRANTED PATENT NUMBER: US7213269
     HIGHEST APPLICATION PUBLICATION NUMBER: US2007094759
     CA INDEXING IS CURRENT THROUGH 1 May 2007 (20070501/UPCA)
     ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 May 2007 (20070501/PD)
```

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.39	886.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 13:19:45 ON 02 MAY 2007